Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 17, 2021
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
Tue, March 16, 2021
[ Tue, Mar 16th 2021
] - WOPRAI
[ Tue, Mar 16th 2021
] - WOPRAI
Joon Lee Upgraded (ANAB) to Strong Buy and Increased Target to $34 on, Mar 16th, 2021
Joon Lee of Truist Securities, Upgraded "AnaptysBio, Inc." (ANAB) to Strong Buy and Increased Target from $27 to $34 on, Mar 16th, 2021.
Joon has made no other calls on ANAB in the last 4 months.
There are 2 other peers that have a rating on ANAB. Out of the 2 peers that are also analyzing ANAB, 1 agrees with Joon's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Nierengarten of "Wedbush" Downgraded from Buy to Hold on, Tuesday, March 9th, 2021
This is the rating of the analyst that currently disagrees with Joon
- Anupam Rama of "JP Morgan" Upgraded from Sell to Buy and Increased Target to $40 on, Thursday, February 11th, 2021
